Wellington Shields & Co. LLC purchased a new stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,500 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas bought a new position in shares of Juno Therapeutics during the third quarter valued at about $293,000. Advisor Group Inc. lifted its position in shares of Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,439 shares in the last quarter. New York State Common Retirement Fund lifted its position in shares of Juno Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 142,700 shares of the biopharmaceutical company’s stock valued at $6,402,000 after purchasing an additional 5,000 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after purchasing an additional 1,229,622 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new position in shares of Juno Therapeutics during the third quarter valued at about $5,428,000. 66.71% of the stock is currently owned by institutional investors.

Juno Therapeutics, Inc. (NASDAQ JUNO) traded down $1.54 on Tuesday, hitting $56.05. 1,395,100 shares of the stock traded hands, compared to its average volume of 2,064,604. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company’s revenue was up 115.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.57) earnings per share. equities research analysts anticipate that Juno Therapeutics, Inc. will post -4.02 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Wellington Shields & Co. LLC Takes $202,000 Position in Juno Therapeutics, Inc. (JUNO)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/14/wellington-shields-co-llc-takes-202000-position-in-juno-therapeutics-inc-juno.html.

JUNO has been the topic of a number of recent analyst reports. Wedbush raised shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target on the stock in a research report on Tuesday, August 29th. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price target (up from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial, Inc. raised their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. Standpoint Research restated a “reduce” rating on shares of Juno Therapeutics in a report on Thursday, August 31st. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $44.00 price objective on shares of Juno Therapeutics in a report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $44.20.

In other news, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the transaction, the executive vice president now owns 79,998 shares in the company, valued at $4,395,890.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders sold 79,670 shares of company stock valued at $3,553,777 in the last quarter. Corporate insiders own 15.26% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.